LCM
ASMB icon

Lynx1 Capital Management’s Assembly Biosciences ASMB Stock Holding History

Lynx1 Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,366
Closed -$188K – 15
2025
Q2 		$188K Buy
+10,366
New +$137K 0.05% 15

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lynx1 Capital Management's ASMB Position: Q3 2025 in Review

Lynx1 Capital Management sold out of Assembly Biosciences (ASMB) in Q3 2025, closing a stake of 10,366 shares — an estimated $188K sold.

Lynx1 Capital Management first reported a position in ASMB in Q2 2025 and held it in 1 quarter. The position peaked at $188K in Q2 2025. 57 funds tracked by Wall St. Rank hold ASMB as of Q3 2025.

  • Lynx1 Capital Management reported no remaining Assembly Biosciences position as of Q3 2025 after selling out during the quarter.
  • Lynx1 Capital Management sold 10,366 Assembly Biosciences shares in Q3 2025, an estimated $188K.
  • Lynx1 Capital Management first reported a position in Assembly Biosciences in Q2 2025 and held it in 1 quarter.
  • Lynx1 Capital Management's Assembly Biosciences position peaked at $188K in Q2 2025.
  • 57 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2025.

Based on Lynx1 Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.